ERBB2 and breast cancer: US yielded a higher specificity than MRI overall (0.72 vs 0.61) and in HR+/HER2+ tumors (0.75 vs 0.44) while both methods were comparable in HR−/HER2− and HR−/HER2+ BC (Table 3).